Our research delves into the field of obesity and metabolic diseases, with a specific focus on characterizing the dysregulation of tissue and cells, as well as the inter-organ dialogues that arise from changes in weight and metabolic status.
Having had access to samples from patients of various metabolic diseases at different progression stages, we have been able to develop novel bioinformatic methods of data integration and analysis.
From these new bioinformatic methods, we develop hypotheses on large-scale approaches to be tested in translational and clinical studies.
In the past five years, we achieved the following key milestones:
Increased knowledge of alterations in immunity and inflammatory status associated with obesity in human adipose tissue deposits, circulation, and digestive tract.
Demonstrated the significance of fibrosis in the alterations observed in adipose tissue of obese individuals, and identified the cellular contributors involved.
Identified significant microbiota dysbiosis in obesity-affected individuals and detected mediators that establish a connection between the imbalance of intestinal bacterial species and organ alterations.
This collective work was published in 106 original articles and approximately fifty journals or book chapters and led to the team obtaining the FRM label. We will capitalize on the results obtained over the next five years by pursuing this translational approach and developing mechanistic aspects.
Moving forward, we aim to investigate the role of the gut microbiome as well as explore the consequences of adipose tissue remodelling in the context of obesity progression and associated complications
We aim to develop a bioinformatics approach founded on systems biology and data integration. This axis is led by physicians in liaison with the clinical services so as to improve new therapeutic strategies by testing the relevance of biomarkers/predictors identified in patients.